Cutaneous Leukocytoclastic Vasculitis Induction Following ChAdOx1 nCoV-19 Vaccine

Shahrigharahkoshan, Shaghayegh; Gagnon, Langis; Mathieu, S.

doi:10.7759/cureus.19005

Cited by 6 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one had cryoglobulinemia. 7 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 36 , 37 Nastro et al 21 reported an 84‐year‐old woman, with history of chronic kidney disease and depressive disorder, developed burning pain on the distal part of right leg and foot, followed by ipsilateral multiple non‐confluent purpuric papules and vesicles few hours after she received the first dose of Pfizer‐BioNTech COVID‐19 vaccine. PCR of a skin swab for varicella‐zoster virus (VZV) resulted positive, and VZV IgM and IgG antibodies were positive.…”

Section: Resultsmentioning

confidence: 99%

“…Twenty cases of COVID‐19‐vaccine triggered‐LCV were noted; three with an elevated anti‐Spike SARS CoV‐2 Antibody titer, two of them had no history of COVID‐19.Oral mucosal involvement was noted in one case. Only one had cryoglobulinemia 7,18–33,36,37 . Nastro et al 21 reported an 84‐year‐old woman, with history of chronic kidney disease and depressive disorder, developed burning pain on the distal part of right leg and foot, followed by ipsilateral multiple non‐confluent purpuric papules and vesicles few hours after she received the first dose of Pfizer‐BioNTech COVID‐19 vaccine.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Abdelmaksoud

Wollina

Temiz

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Currently the most powerful tool in combating the COVID‐19 pandemic is vaccination against SARS‐CoV‐2. A growing percentage of the world's population is being vaccinated. Various vaccines are worldwide on the market. Several adverse reactions have been reported as a part of post‐marketing surveillance of COVID‐19 vaccines. Among the possible adverse events, cutaneous vasculitis has occasionally been reported. We present a narrative review on cutaneous vasculitis related to COVID‐19‐vaccination to summarize clinical findings, histopathology, treatment and outcome. We searched for “COVID vaccine”, “COVID vaccination” AND “cutaneous vasculitis” in PUBMED. Articles in English have been selected, from inception to December 2021, and analyzed for patient's characteristics, type of vaccine, time of appearance of cutaneous vasculitis and clinico‐histopathologic type. Treatment and outcome have also been considered in this narrative review. Two new unpublished cases of ours were added. Cutaneous vasculitis is a rare adverse event to COVID‐19 vaccination. It has been observed with mRNA and adenovirus‐vector vaccines. IgA vasculitis, lymphocytic and ANCA‐associated vasculitis, leukocytoclastic and urticarial vasculitis have been reported. This adverse event can occur after first or second shot. Most cases run a mild to moderate course. Cornerstone of medical treatment are systemic corticosteroids. Complete remission could be achieved in most patients. Vasculitis may not be considered as a contraindication of vaccination, being uncommonly reported and shows a favorable prognosis. The benefit of the vaccination remains high especially for immunocompromised patients. COVID‐vaccine induced vasculitis is important in the differential diagnosis of purpuric and vasculitis disorders.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Abdelmaksoud

Wollina

Temiz

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…The association between vaccination and development of CSVV has been reported in literature with various vaccines, namely: influenza, hepatitis A, hepatitis B, bacillus Calmette-Guérin, anthrax, human papillomavirus, measles-mumps-rubella, and pneumococcal vaccines. 25 Among the available COVID-19 vaccines, LCV has been reported with messenger RNA-based vaccines (BNT162b2 [Pfizer-BioNTech] 6,8-12 and mRNA-1273 [Moderna], 6,7 adenoviral vectorbased vaccines [ChAdOx1 nCoV-19; Oxford-AstraZeneca]), [13][14][15][16][17][18][19] and inactivated vaccines (Covaxin, 20,21 Sinovac, 22,23 and unspecified inactivated vaccines 24 ) (Table 1). Most of the reported vaccine-related cutaneous LCV were limited to the skin and only few were associated with systemic involvement.…”

Section: Discussion and Review Of Literaturementioning

confidence: 99%

“…Among the available COVID‐19 vaccines, LCV has been reported with messenger RNA‐based vaccines (BNT162b2 [Pfizer‐BioNTech] 6,8–12 and mRNA‐1273 [Moderna], 6,7 adenoviral vector‐based vaccines [ChAdOx1 nCoV‐19; Oxford‐AstraZeneca]), 13–19 and inactivated vaccines (Covaxin, 20,21 Sinovac, 22,23 and unspecified inactivated vaccines 24 ) (Table 1). Most of the reported vaccine‐related cutaneous LCV were limited to the skin and only few were associated with systemic involvement 7,9,11,19,23 .…”

Section: Discussion and Review Of Literaturementioning

confidence: 99%

Extensive cutaneous leukocytoclastic vasculitis after Sinopharm vaccine: Case report and review of the literature

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Common cutaneous manifestations are summarized in Supplementary Table 4 . 12 , 17 - 24 , 27 , 43 , 44 , 54 - 77 These included delayed large local arm reactions, local injection site reactions, urticaria or urticarial reactions, morbilliform or maculopapular eruptions, pityriasis rosea (PR)-like eruptions, pernio or chilblains, dermatitis, cutaneous small vessel vasculitis (CSVV), ecchymosis, petechiae, purpura, and lymphadenopathy. The reactions were mainly reported with Moderna and Pfizer and occasionally with AstraZeneca, Sinovac, and Covaxin.…”

Section: Narrative Review Of Common and Uncommon Cutaneous Manifestat...mentioning

confidence: 99%

Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review

Mahmood

Cyr

et al. 2023

J Cutan Med Surg

View full text Add to dashboard Cite

As coronavirus disease (COVID-19) vaccines continue to be administered, dermatologists play a critical role in recognizing and treating the cutaneous manifestations (CM) associated with the vaccines. Adverse cutaneous reactions of COVID-19 vaccines reported in the literature range from common urticarial to rare vesiculobullous reactions. In this study, we performed a (1) scoping review to assess the occurrences of vesicular, papulovesicular, and bullous CMs of COVID-19 vaccines and their respective treatments, and (2) a narrative review discussing other common and uncommon CMs of COVID-19 vaccines. Thirty-six articles were included in the scoping review, and 66 articles in the narrative review. We found that vesicular, papulovesicular, and bullous lesions are infrequent, reported mostly after the first dose of Moderna or Pfizer vaccines. Eleven of the 36 studies reported vesicular reactions consistent with activation or reactivation of the herpes zoster virus. Most vesicular and bullous lesions were self-limited or treated with topical corticosteroids. Other CMs included injection-site, urticarial or morbilliform reactions, vasculitis, toxic epidermal necrolysis, and flaring of or new-onset skin diseases such as psoriasis. Treatments for CMs included topical or oral corticosteroids, antihistamines, or no treatment in self-limited cases. Although most CMs are benign and treatable, the data on the effect of systemic corticosteroids and immunosuppressive therapies on the immunogenicity of COVID-19 vaccines is limited. Some studies report reduced immunogenicity of the vaccines after high-dose corticosteroids use. Physicians may consult local guidelines where available when recommending COVID-19 vaccines to immunosuppressed patients, and when using corticosteroids to manage the CMs of COVID-19 vaccines.

show abstract

Cutaneous Leukocytoclastic Vasculitis Induction Following ChAdOx1 nCoV-19 Vaccine

Cited by 6 publications

References 13 publications

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Extensive cutaneous leukocytoclastic vasculitis after Sinopharm vaccine: Case report and review of the literature

Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review

Contact Info

Product

Resources

About